Nature's secret for cancer drugs, Pg13

Key Highlights:

• Scientists at the University of Warwick, in collaboration with Monash University, have uncovered how bacterial enzymes coordinate to produce anticancer compounds.
• This discovery resolves a long-standing challenge in the field of combinatorial biosynthesis, which aims to create new drug variants.
• The research provides a new strategy for designing future cancer therapies, potentially accelerating the development of treatments for hard-to-treat cancers.
• The family of compounds studied includes Romidepsin (Istodax), an FDA-approved drug used for certain blood cancers.

Detailed Insights:

• The study, published in Nature Communications, revealed the "mix and match" mechanism employed by bacteria to assemble diverse anticancer molecules.
• Previously, the lack of understanding regarding how these bacterial enzymes interact had limited progress in harnessing combinatorial biosynthesis for drug development.
• The breakthrough identified small molecular regions, termed 'docking domains,' which act as connectors between the core drug assembly machinery and various component-building enzymes.
• Romidepsin (Istodax) functions as a histone deacetylase (HDAC) inhibitor, a class of drugs that block enzymes regulating gene expression to inhibit cancer cell growth.
• This new understanding offers a blueprint for engineering synthetic pathways to generate novel anticancer drug candidates with improved properties like potency and selectivity.
• The research also successfully identified the biosynthetic pathway for FR-901375, a chemically related compound whose natural production mechanism was previously unknown.

Scientific/Technical Concepts Involved:

• Combinatorial Biosynthesis: A genetic engineering approach to modify natural product biosynthetic pathways to generate new and altered drug structures.
• Bacterial Enzymes: Proteins produced by bacteria that catalyze specific biochemical reactions, essential for synthesizing complex organic molecules.
• Histone Deacetylase (HDAC) Inhibitors: A class of anticancer drugs that interfere with histone deacetylase enzymes, thereby influencing gene expression and cancer cell proliferation.
• Romidepsin (Istodax): An FDA-approved drug belonging to the HDAC inhibitor class, primarily used in the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.